Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 3,229 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Solution Clear all
Completed Phase 2 Interventional Results available

Early Intervention With Fluoxetine in Autism

NCT00183339
View directory record Official record
Conditions
Autistic Disorder
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Months to 58 Months
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2014 · Synced Oct 22, 2026, 8:39 AM EDT
Not listed Not applicable Interventional

Are Superficial Parasternal Intercostal Plane (SPIP) Blocks With Bupivacaine and With or Without Adjuvants Helpful for Post-operative Pain After Coronary Artery Bypass Grafting?

NCT05003765
View directory record Official record
Conditions
Post-operative Pain Management
Interventions
Bupivacaine 0.25% Injectable Solution, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Bupivacaine 0.25% Injectable Solution, Magnesium Sulfate 200 mg, Buprenorphine 300 mcg
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 22, 2026, 8:39 AM EDT
Active, not recruiting Phase 3 Interventional

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

NCT05776277
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Iltamiocel, Placebo
Biological · Other
Lead sponsor
Cook MyoSite
Industry
Eligibility
18 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
La Jolla, California • Orange, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

NCT02597777
View directory record Official record
Conditions
Oily Skin
Interventions
Acetyl Hexapeptide-8, Placebo vehicle
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 22, 2026, 8:39 AM EDT
Active, not recruiting Phase 3 Interventional

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

NCT05345171
View directory record Official record
Conditions
OTC Deficiency
Interventions
DTX301, Placebo, Oral Corticosteroids, Placebo for oral corticosteroids, Sodium Acetate
Genetic · Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
12 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Phase 2 Interventional Results available

Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

NCT01300728
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
NewGam 10% IVIG, Placebo
Drug · Other
Lead sponsor
Sutter Health
Other
Eligibility
50 Years to 84 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study of PTI-125 in Healthy Volunteers

NCT03784300
View directory record Official record
Conditions
Alzheimer Disease, Early Onset, Alzheimer Disease
Interventions
50 mg PTI-125, 100 mg PTI-125, 200 mg PTI-125
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 22, 2026, 8:39 AM EDT
Terminated Phase 4 Interventional Results available

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

NCT03756454
View directory record Official record
Conditions
Clostridia Difficile Colitis, Clostridium; Sepsis
Interventions
Bezlotoxumab, Normal Saline
Biological · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Phase 3 Interventional Results available

Lateral Canthal Rhytides With Medium Depth Chemical Peel With or Without Pretreatment With Botulinum Toxin A

NCT01586819
View directory record Official record
Conditions
Wrinkles
Interventions
Botulinum Toxin, Chemical Peel Only
Drug · Procedure
Lead sponsor
Loyola University
Other
Eligibility
30 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
La Grange Park, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 22, 2026, 8:39 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

NCT01403064
View directory record Official record
Conditions
Oral Mucositis
Interventions
ALD518, 0.9% saline
Biological · Drug
Lead sponsor
CSL Behring
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
13
States / cities
Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 22, 2026, 8:39 AM EDT
Recruiting Phase 4 Interventional

Lactated Ringer's and Dextrose 5% vs Only Lactated Ringer's in Labor

NCT07124130
View directory record Official record
Conditions
Induced Labor
Interventions
5% Dextrose (D5) in Normal Saline (NS), Lactate Ringer
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Phase 2 Interventional

Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage

NCT00827892
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
Pioglitazone, Placebo Control
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Beverage Hydration Index: Assessment of Four Rehydration Solutions

NCT06272435
View directory record Official record
Conditions
Hydration
Interventions
Multiplier, Sugar Free, Sugar Free with Amino Acids, Water
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 22, 2026, 8:39 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Safety Voice for Ergonomics as a Preventive Approach for Work-related Musculoskeletal Disorders in Masonry Apprentices

NCT02676635
View directory record Official record
Conditions
Work Related Musculoskeletal Disorders
Interventions
Ergonomics training and/or Safety Voice training
Behavioral
Lead sponsor
Eastern Washington University
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 22, 2026, 8:39 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Motivational Interviewing to Improve Oral Hygiene in Adolescent Orthodontic Patients

NCT07164989
View directory record Official record
Conditions
Gingivitis, DMFT Index, Dental Plaque Index, Oral Hygiene Education Methods, Oral Hygiene Reinforcement During Fixed Orthodontic Treatment, Motivational Interview, OHI
Interventions
Motivational Interviewing-Based Counseling, Standard Oral Health Education
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 19 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 22, 2026, 8:39 AM EDT
Not listed Phase 3 Interventional

Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

NCT05165290
View directory record Official record
Conditions
Elevated Intraocular Pressure
Interventions
Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
Drug
Lead sponsor
TearClear Corp
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
20
States / cities
Garden Grove, California • Glendale, California • Mission Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types

NCT03466060
View directory record Official record
Conditions
Visual Acuity, Slit Lamp Biomicroscopy (Corneal Staining Assessment)
Interventions
Opti-Free : RevitaLens / Clear Care : RevitaLens, Opti-Free : RevitaLens / RevitaLens : Clear Care, Clear Care : RevitaLens/ Opti-Free : RevitaLens, Clear Care : RevitaLens / RevitaLens : Opti-Free, RevitaLens : Clear Care/ Opti-Free : RevitaLens, RevitaLens : Clear Care / RevitaLens : Opti-Free, RevitaLens : Opti-Free / Clear Care : RevitaLens, RevitaLens : Opit-Free / RevitaLens : Clear Care
Device
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
5
States / cities
Anaheim, California • Berkeley, California • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy

NCT00733096
View directory record Official record
Conditions
Lumbosacral Radiculopathy
Interventions
etanercept, methylprednisolone, normal saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fort Bragg, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2012 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease

NCT02218489
View directory record Official record
Conditions
Blepharitis
Interventions
KPI-121, Vehicle
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • Artesia, California • Mission Hills, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 22, 2026, 8:39 AM EDT
Not yet recruiting Phase 2 Interventional

Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome

NCT04381897
View directory record Official record
Conditions
Cornelia de Lange Syndrome
Interventions
N-acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
13 Years to 35 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 22, 2026, 8:39 AM EDT
Recruiting Phase 2 Interventional

Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults

NCT06526208
View directory record Official record
Conditions
Autism Spectrum Disorder, Anxiety
Interventions
MB-IMP, Placebo
Drug · Other
Lead sponsor
Southwest Autism Research & Resource Center
Other
Eligibility
18 Years to 45 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis

NCT01860976
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Abatacept, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Colorado Springs, Colorado • Bridgeport, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

One-month Clinical Evaluation of Oté Sensation Multi-Purpose Solution Care System

NCT03278223
View directory record Official record
Conditions
Myopia, Hyperopia
Interventions
Test solution, Control solution
Device
Lead sponsor
OTE North America
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
5
States / cities
Sarasota, Florida • Pittsburg, Kansas • Vestal, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 22, 2026, 8:39 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis

NCT02702180
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Molgramostim, Placebo, PARI eFlow nebulizer system
Drug · Device
Lead sponsor
Savara Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Gainesville, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 22, 2026, 8:39 AM EDT